Utrecht’s Laigo Bio completes final close of €17 million Seed round to advance cancer and autoimmune therapies | EU-Startups
Laigo Bio, a Utrecht-based BioTech firm focused on protein degradation for targeted therapies, has concluded the second close of its Seed funding round, raising an extra €5.5 million, bringing the ...

Source: EU-Startups
Laigo Bio, a Utrecht-based BioTech firm focused on protein degradation for targeted therapies, has concluded the second close of its Seed funding round, raising an extra €5.5 million, bringing the total amount raised to €17 million. The €5.5 million raised includes additional funding of €4 million secured from new co-lead investor Biovance Capital and €1.5 […] The post Utrecht’s Laigo Bio completes final close of €17 million Seed round to advance cancer and autoimmune therapies appeared first on EU-Startups.